Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Avalyn Pharma announced the completion of patient enrollment for its global Phase 2b MIST trial evaluating AP01 for progressive pulmonary fibrosis. The trial overenrolled with 398 patients, and topline data are expected in late 2027. The company is also progressing Phase 2 AURA trial for AP02 and plans to initiate Phase 1 for AP03 by end of 2026. A…